ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting
March 14, 2023 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
SAN MATEO, Calif. and SINGAPORE, March 14, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change
March 10, 2023 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
SAN MATEO, Calif. and SINGAPORE, March 10, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing...
ASLAN Pharmaceuticals to Host Virtual Research and Development Day on Novel DHODH Inhibitor Farudodstat for Alopecia Areata
March 08, 2023 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
SAN MATEO, Calif. and SINGAPORE, March 08, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals to Advance Novel DHODH Inhibitor Farudodstat Into Phase 2 Clinical Testing as Potential First-In-Class Treatment for Alopecia Areata
February 28, 2023 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
Alopecia areata (AA) is a common autoimmune disease affecting over 700,000 patients in the US and is driven by loss of immune privilege (IP) in the hair follicles and subsequent attack by...
ASLAN Pharmaceuticals Announces $20M Private Placement Led by BVF Partners L.P. With the Potential to Receive Up to an Additional $80M
February 24, 2023 06:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
ASLAN to receive $20 million in financing with the potential to receive up to an additional $80 million for an aggregate of $100 million to continue advancing the clinical development of eblasakimab...
ASLAN Pharmaceuticals Announces Completion of Recruitment in Phase 2b TREK-AD Study of Eblasakimab in Atopic Dermatitis Patients
February 24, 2023 05:59 ET
|
ASLAN PHARMACEUTICALS LIMITED
The TRials with EblasaKimab in Atopic Dermatitis (TREK-AD) study has enrolled the final patient Topline results expected in early July 2023 SAN MATEO, Calif. and SINGAPORE, Feb. 24, 2023 (GLOBE...
ASLAN Pharmaceuticals and Thermo Fisher Scientific Announce Partnership to Manufacture High Concentration Formulation of Eblasakimab for Future Studies
January 03, 2023 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
Thermo Fisher Scientific to provide biologic manufacturing expertise and scale-up capacity to manage the clinical supply of eblasakimab for future Phase 3 studies A high concentration formulation of...
ASLAN Pharmaceuticals Announces Participation in January Investor Conferences
December 16, 2022 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
SAN MATEO, Calif. and SINGAPORE, Dec. 16, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals Announces First Patient Screened in Study of Eblasakimab in Dupilumab Experienced Atopic Dermatitis Patients
December 15, 2022 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
The TRials with EblasaKimab in Dupilumab eXperienced atopic dermatitis patients (TREK-DX) study will evaluate eblasakimab in a patient population with few safe treatment optionsThe study will enroll...
ASLAN Pharmaceuticals to Participate in a Fireside Chat at 34th Annual Piper Sandler Healthcare Conference
November 21, 2022 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
SAN MATEO, Calif. and SINGAPORE, Nov. 21, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...